GlassScriptPhysician profile
Chaim Poper
NPI 1346745908
$1,514.32
in general payments reported to CMS, 2019-2025
20 companies · $722 in 2025
The $722 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $259 · 2023: $338 · 2024: $196 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $301.51 | 2023-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Novo Nordisk INC | $254.78 | 2022-2024 | Rybelsus, Ozempic |
| Amgen INC. | $150.00 | 2025 | Otezla |
| Astrazeneca Pharmaceuticals LP | $144.90 | 2024-2025 | Farxiga |
| Abbvie INC. | $124.83 | 2023 | |
| Pfizer INC. | $84.31 | 2023-2024 | |
| Xeris Pharmaceuticals, INC. | $79.36 | 2025 | Recorlev, Gvoke Hypopen |
| Exact Sciences Corporation | $66.80 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $41.78 | 2022-2023 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.54 | 2025 | Jardiance |
| Neurocrine Biosciences, INC. | $29.50 | 2023 | Ingrezza |
| Ardelyx, INC. | $29.40 | 2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $27.89 | 2025 | Vpriv |
| Lilly USA, LLC | $25.59 | 2024 | Mounjaro |
| Insulet Corporation | $24.12 | 2025 | Omnipod |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $22.04 | 2025 | Rexulti |
| Meridian Bioscience INC. | $18.80 | 2024 | |
| Almatica Pharma LLC | $16.99 | 2025 | Loreev Xr, Teriparatide |
| Eisai INC. | $16.98 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $15.20 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chaim Poper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.